Method of treating glioma
AssigneeThe Board of Trustees of the Leland Stanford Junior University
InventorsMichelle Monje-Deisseroth, Humsa S. Venkatesh
Life of this patent
Estimating the term…
Abstract
Methods of treating glioma are provided. Aspects of the invention include administering a therapeutically-effective amount of an agent that inhibits the activity of one or more neuronal activity-regulated proteins selected from: neuroligin-3, brain-derived neurotrophic factor (BDNF), or brevican, to a patient with a glioma. In certain embodiments, the subject methods involve treating a neurological dysfunction, reducing invasion of a glioma cell into brain tissue, and/or reducing the growth rate of a glioma in the patient. Also provided herein are methods for identifying an agent that modulates the mitotic index of a glial cell, and methods for stimulating the proliferation of a glial cell. Kits that find use in practicing the subject methods are also provided.
Claims16
A method of reducing a neurological dysfunction in a patient with a glioma tumor, the method comprising:
- administering to the patient a therapeutically-effective amount of an ADAM10 inhibitor INCB7839 that reduces secretion of neuroligin-3 in the glioma tumor;
- and
- measuring a level of secreted neuroligin-3 in cerebrospinal fluid (CSF) from the patient.
A method of preventing a glioma tumor cell from invading a brain tissue in a patient, the method comprising:
- administering to the patient a therapeutically-effective amount of an ADAM10 inhibitor INCB7839 that reduces secretion of neuroligin-3;
- and
- measuring a level of secreted neuroligin-3 in cerebrospinal fluid (CSF) from the patient.
A method of reducing a growth rate of a glioma tumor cell in a patient, the method comprising:
- administering to the patient a therapeutically-effective amount of an ADAM10 inhibitor INCB7839 that reduces secretion of neuroligin-3;
- and
- measuring a level of secreted neuroligin-3 in cerebrospinal fluid (CSF) from the patient.
A method for treating a glioma tumor in a subject, the method comprising:
- administering to the subject a therapeutically-effective amount of an ADAM10 inhibitor INCB7839 that reduces secretion of neuroligin-3.
Dependencies are inferred from the claim text.